Biocryst Pharmaceuticals (BCRX) EBT Margin Growth (1y) (2011 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) EBT Margin Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.56 Bn | 197.57 Bn | 7.24 Bn | 1,045.00 |
| 2 | Gilead Sciences | 181.34 Bn | 178.16 Bn | 6.22 Bn | -16,571.00 |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | -153.00 |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | -571.00 |
| 5 | Argenx Se | 61.55 Bn | 56.37 Bn | 1.37 Bn | 553.00 |
| 6 | Moderna | 54.32 Bn | 49.19 Bn | 52.00 Mn | 4,709.00 |
| 7 | Alnylam Pharmaceuticals | 34.32 Bn | 31.01 Bn | 992.69 Mn | 1,911.00 |
| 8 | Biogen | 31.24 Bn | 29.95 Bn | 1.96 Bn | -2,328.00 |
| 9 | Roivant Sciences | 30.17 Bn | 30.17 Bn | 1.16 Mn | -801,907.00 |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn | 3,244.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3,244.00 |
| Mar 31, 2026 | -46,136.00 |
| Dec 31, 2025 | 3.51 Mn |
| Sep 30, 2025 | 1,909.00 |
| Jun 30, 2025 | 1,541.00 |
| Mar 31, 2025 | 3,827.00 |
| Dec 31, 2024 | 4,786.00 |
| Sep 30, 2024 | 2,981.00 |
| Jun 30, 2024 | 7,898.00 |
| Mar 31, 2024 | 3,882.00 |
| Dec 31, 2023 | 2,222.00 |
| Sep 30, 2023 | 1,277.00 |
| Jun 30, 2023 | -191.00 |
| Mar 31, 2023 | 7,149.00 |
| Dec 31, 2022 | -5,692.00 |
| Sep 30, 2022 | 8,937.00 |
| Jun 30, 2022 | -204.00 |
| Mar 31, 2022 | 18,923.00 |
| Dec 31, 2021 | 139,850.00 |
| Sep 30, 2021 | 61,210.00 |